Australian universities produce world-class research. Our researchers publish in top journals, win international awards, and make genuine breakthroughs in materials science, medical technology, and agricultural innovation.

Very little of this research becomes commercial products or companies.

The standard explanation is that Australian researchers don’t understand business or don’t want to commercialize. That’s mostly wrong.

The real problem is university tech transfer offices that actively prevent commercialization while claiming to enable it.

Unrealistic Valuation Expectations

A researcher develops a novel battery chemistry in the lab. It’s promising but unproven at scale. It needs 2-3 years of development before it’s commercially viable.

The university’s tech transfer office values the IP at $5 million and wants 15% equity in any spinout company, plus royalties on future revenue.

No investor will fund that deal. The technology isn’t worth $5 million in its current state. The equity stake plus royalties makes the cap table unattractive for early-stage investors.

The research sits unlicensed while the university holds out for terms that don’t match market reality.

Process Delays Kill Momentum

A startup wants to license university technology. The researcher is enthusiastic. The company has seed funding ready.

It takes 9-14 months to negotiate the license agreement. By the time terms are finalized, the seed funding has been deployed elsewhere, the market window has shifted, or the founding team has moved on.

Tech transfer offices are staffed by lawyers, not operators. They optimize for risk minimization and revenue maximization, not for speed or startup success.

Conflicts Between Research and Commercial Timelines

Universities want researchers to publish. Publishing establishes priority and builds reputation.

Commercial partners want IP protection before disclosure. You can’t patent something after it’s been publicly published.

Tech transfer offices often fail to coordinate filing provisional patents before publication deadlines. The IP becomes unpatentable, but the university blames the researcher for publishing “too early.”

Researchers end up forced to choose between career advancement (publishing) and commercialization (protecting IP). Most choose publishing because that’s what universities actually reward.

Equity Stakes Prevent Follow-On Funding

Universities routinely take 5-15% equity in spinout companies. That equity sits on the university’s balance sheet, not in a fund that can support follow-on rounds.

When the company needs Series A funding, investors see a major shareholder (the university) that won’t participate in future rounds and can’t provide strategic value beyond the initial IP.

The equity structure becomes a liability. Investors either pass on the deal or require the university to dilute significantly, which the university refuses to do.

Exclusive Licenses Block Multiple Applications

A university licenses technology exclusively to Company A for medical applications. Company B wants to license the same technology for industrial use - a different market, no overlap.

The tech transfer office says no because they’ve granted an exclusive license. Company A isn’t pursuing industrial applications and never will, but they’ve blocked anyone else from doing it.

Non-exclusive or field-limited licenses would solve this, but universities default to exclusive licenses because they’re simpler to negotiate.

Success Metrics Are Wrong

Tech transfer offices are measured on:

• IP filings (quantity, not quality)
• Licensing revenue (which incentivizes holding out for big deals)
• Number of patents granted

They’re not measured on:

• Number of companies created
• Follow-on investment raised by spinouts
• Commercial products brought to market
• Jobs created

The incentive structure optimizes for patent portfolios and royalty revenue, not for economic impact or successful commercialization.

International Comparison

MIT’s tech transfer office helped create over 140 companies in the past decade. Stanford’s office supported the formation of companies like Google, Cisco, and Sun Microsystems.

Australian universities’ combined output is a fraction of that, despite comparable research quality.

The difference isn’t researcher entrepreneurship. It’s institutional approach.

Stanford takes minimal equity, focuses on getting technology into founders’ hands quickly, and measures success by company formation, not licensing revenue.

Australian universities do the opposite.

Researcher Frustration

Talk to university researchers who’ve tried to commercialize their work. The consistent theme is frustration with their own tech transfer office.

Researchers partner with external companies to work around the office. They wait until they leave the university to pursue commercialization. They deliberately develop new IP outside the university system to avoid the licensing nightmare.

That’s a massive waste of research investment.

The Funding Mismatch

Universities fund basic research through grants. That gets technology to proof-of-concept in the lab.

Commercial development requires prototype building, market validation, regulatory approval, and scaling - none of which universities fund.

Tech transfer offices expect external investors to fund that gap, but they want terms as if the technology is already developed.

The right model is a university-backed fund that provides gap funding to take technology from TRL 4 to TRL 7, at which point external investors can realistically assess commercial viability.

Most Australian universities don’t have this. They expect researchers or external investors to fund the gap while the university holds expensive IP.

Exceptions Exist

UNSW’s Founders program and University of Queensland’s Ventures fund are better models. They provide pre-seed funding, mentoring, and startup support without extracting punitive terms.

Monash’s commercialization team has streamlined licensing processes and takes more realistic equity positions.

These exceptions prove the model can work. But they’re not yet the norm across the sector.

What Needs to Change

Universities need to:

1. Price IP realistically - unproven lab technology isn’t worth millions
2. Accelerate licensing - 30-60 days for standard agreements, not 9 months
3. Take smaller equity stakes - 2-5% is reasonable for early-stage IP
4. Provide gap funding - bridge the valley between research and commercial readiness
5. Measure commercial outcomes - companies created and products launched, not just patents filed

The current system is optimized for universities to protect their interests. That’s understandable, but it prevents the commercialization that’s supposedly the goal.

Researchers will continue to work around tech transfer offices until universities fix the incentives and processes.

Australian research is excellent. Our commercialization infrastructure is the bottleneck. Fixing that requires universities to admit the current model doesn’t work and adopt the approaches that actually generate spinout companies elsewhere.

Until that happens, we’ll keep publishing world-class research that never becomes commercial products. That’s a waste of research funding and economic opportunity.